Comparison of the Automated Chromogranin A Assay Using KRYPTOR Instrumentation with the Manual IRMA Assay of CisBio Abstract #448

Introduction: Chromogranin A (CgA) has become the most important tumor marker for neuroendocrine tumors (NET) during the last decade. To meet the need for high throughput and rapid measurements, the fully automated Thermo Scientific BRAHMS KRYPTOR CgA assay has been developed.
Aim(s): To evaluate the analytical performances of the KRYPTOR assay and to compare this assay with the immunoradiometric (IRMA) assay of CisBio.
Materials and methods: The KRYPTOR assay is a sandwich immunoassay using Time Resolved Amplified Cryptate Emission technology. The incubation time is 29 minutes; measuring range is 6-1,000,000 µg/l. The CisBio assay is a solid-phase, two-site IRMA assay. Ninety-nine samples of healthy individuals and 199 patients with a NET were measured with the KRYPTOR and the CisBio assay.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Catharina M Korse

To read results and conclusion, please login ...

Further abstracts you may be interested in

#112 Chromogranin A is a sensitive marker for detection of recurrence in neuroendocrine tumors
Introduction: The chromogranin family is a family of large acidic proteins which are expressed in neuroendocrine cells. There are several members in this family (Chromogranin A, B (CgA and CgB) and the secretogranins). Here, we show that CgA is an excellent marker to detect recurrence in neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eva Tiensuu Janson
#953 Comparison of Diagnostic Methods in the Evaluation of Pancreatic and Duodenal Gastrinomas
Introduction: Gastrinomas are neuroendocrine tumors, mainly located in the duodenum or the pancreas, that secrete gastrin and cause a clinical syndrome known as ZES.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: M.D., PhD. Peter Hyrdel
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#997 Comparison of Different Diagnostic Methods for the Assessment of Progression in Patients with Neuroendocrine Tumors (NET)
Introduction: Different imaging and laboratory methods are used to evaluate patients with NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Florian Keplinger
#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?
Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: drs. Kimberly Kamp
Keywords: GEP-NET, CgA, prognosis